FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2587429794> ?p ?o ?g. }

• W2587429794 endingPage "412" @default.
• W2587429794 startingPage "404" @default.
• W2587429794 abstract "Background Vismodegib, a first-in-class Hedgehog-pathway inhibitor, is approved for use in adults with advanced basal-cell carcinoma. Patients with multiple basal-cell carcinomas, including those with basal-cell nevus (Gorlin) syndrome, need extended treatment. We assessed the safety and activity of two long-term intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas. Methods In this randomised, regimen-controlled, double-blind, phase 2 trial, we enrolled adult patients with multiple basal-cell carcinomas, including those with basal-cell nevus syndrome, who had one or more histopathologically confirmed and at least six clinically evident basal-cell carcinomas. From a centralised randomisation schedule accessed via an interactive voice or web-based response system, patients were randomly assigned (1:1) to treatment group A (150 mg oral vismodegib per day for 12 weeks, then three rounds of 8 weeks of placebo daily followed by 12 weeks of 150 mg vismodegib daily) or treatment group B (150 mg oral vismodegib per day for 24 weeks, then three rounds of 8 weeks of placebo daily followed by 8 weeks of 150 mg vismodegib daily). Treatment assignment was stratified by diagnosis of basal-cell nevus syndrome, geographical region, and immunosuppression status. The primary endpoint was percentage reduction from baseline in the number of clinically evident basal-cell carcinomas at week 73. The primary analysis was by intention to treat. The safety population included all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT01815840, and the study is ongoing. Findings Between April 30, 2013, and April 9, 2014, 229 patients were randomly assigned treatment, 116 in treatment group A and 113 in treatment group B. The mean number of basal-cell carcinoma lesions at week 73 was reduced from baseline by 62·7% (95% CI 53·0–72·3) in treatment group A and 54·0% (43·6–64·4) in treatment group B. 216 (95%) of 227 patients included in the safety analysis had at least one treatment-emergent adverse event deemed to be related to study treatment (107 [94%] of 114 in treatment group A and 109 [97%] of 113 in treatment group B). The most common grade 3 or worse treatment-related adverse events were muscle spasms (four [4%] patients in treatment group A vs 12 [11%] in treatment group B), increased blood creatine phosphokinase (one [1%] vs four [4%]), and hypophosphataemia (zero vs three [3%]). Serious treatment-emergent events were noted in 22 (19%) patients in treatment group A and 19 (17%) patients in treatment group B. Four (2%) patients died from adverse events; one (pulmonary embolism in treatment group A) was possibly related to treatment. Interpretation Both intermittent dosing schedules of vismodegib seemed to show good activity in long-term regimens in patients with multiple basal-cell carcinomas. Further study is warranted. Funding F Hoffmann-La Roche." @default.
• W2587429794 created "2017-02-17" @default.
• W2587429794 creator A5002644565 @default.
• W2587429794 creator A5005926526 @default.
• W2587429794 creator A5011257308 @default.
• W2587429794 creator A5015677243 @default.
• W2587429794 creator A5019246724 @default.
• W2587429794 creator A5034365278 @default.
• W2587429794 creator A5043008500 @default.
• W2587429794 creator A5044736874 @default.
• W2587429794 creator A5050771255 @default.
• W2587429794 creator A5066672443 @default.
• W2587429794 creator A5068933307 @default.
• W2587429794 creator A5079760997 @default.
• W2587429794 creator A5084395446 @default.
• W2587429794 date "2017-03-01" @default.
• W2587429794 modified "2023-10-16" @default.
• W2587429794 title "Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial" @default.
• W2587429794 cites W1990453562 @default.
• W2587429794 cites W2031377991 @default.
• W2587429794 cites W2099120699 @default.
• W2587429794 cites W2101616608 @default.
• W2587429794 cites W2157376707 @default.
• W2587429794 cites W2162564067 @default.
• W2587429794 cites W2486839133 @default.
• W2587429794 cites W4237121156 @default.
• W2587429794 doi "https://doi.org/10.1016/s1470-2045(17)30072-4" @default.
• W2587429794 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28188086" @default.
• W2587429794 hasPublicationYear "2017" @default.
• W2587429794 type Work @default.
• W2587429794 sameAs 2587429794 @default.
• W2587429794 citedByCount "138" @default.
• W2587429794 countsByYear W25874297942016 @default.
• W2587429794 countsByYear W25874297942017 @default.
• W2587429794 countsByYear W25874297942018 @default.
• W2587429794 countsByYear W25874297942019 @default.
• W2587429794 countsByYear W25874297942020 @default.
• W2587429794 countsByYear W25874297942021 @default.
• W2587429794 countsByYear W25874297942022 @default.
• W2587429794 countsByYear W25874297942023 @default.
• W2587429794 crossrefType "journal-article" @default.
• W2587429794 hasAuthorship W2587429794A5002644565 @default.
• W2587429794 hasAuthorship W2587429794A5005926526 @default.
• W2587429794 hasAuthorship W2587429794A5011257308 @default.
• W2587429794 hasAuthorship W2587429794A5015677243 @default.
• W2587429794 hasAuthorship W2587429794A5019246724 @default.
• W2587429794 hasAuthorship W2587429794A5034365278 @default.
• W2587429794 hasAuthorship W2587429794A5043008500 @default.
• W2587429794 hasAuthorship W2587429794A5044736874 @default.
• W2587429794 hasAuthorship W2587429794A5050771255 @default.
• W2587429794 hasAuthorship W2587429794A5066672443 @default.
• W2587429794 hasAuthorship W2587429794A5068933307 @default.
• W2587429794 hasAuthorship W2587429794A5079760997 @default.
• W2587429794 hasAuthorship W2587429794A5084395446 @default.
• W2587429794 hasConcept C126322002 @default.
• W2587429794 hasConcept C126894567 @default.
• W2587429794 hasConcept C142724271 @default.
• W2587429794 hasConcept C143998085 @default.
• W2587429794 hasConcept C168563851 @default.
• W2587429794 hasConcept C203092338 @default.
• W2587429794 hasConcept C204787440 @default.
• W2587429794 hasConcept C27081682 @default.
• W2587429794 hasConcept C2777288759 @default.
• W2587429794 hasConcept C2778804307 @default.
• W2587429794 hasConcept C2779545874 @default.
• W2587429794 hasConcept C2781413609 @default.
• W2587429794 hasConcept C2908647359 @default.
• W2587429794 hasConcept C2909761261 @default.
• W2587429794 hasConcept C3019992690 @default.
• W2587429794 hasConcept C71924100 @default.
• W2587429794 hasConcept C99454951 @default.
• W2587429794 hasConceptScore W2587429794C126322002 @default.
• W2587429794 hasConceptScore W2587429794C126894567 @default.
• W2587429794 hasConceptScore W2587429794C142724271 @default.
• W2587429794 hasConceptScore W2587429794C143998085 @default.
• W2587429794 hasConceptScore W2587429794C168563851 @default.
• W2587429794 hasConceptScore W2587429794C203092338 @default.
• W2587429794 hasConceptScore W2587429794C204787440 @default.
• W2587429794 hasConceptScore W2587429794C27081682 @default.
• W2587429794 hasConceptScore W2587429794C2777288759 @default.
• W2587429794 hasConceptScore W2587429794C2778804307 @default.
• W2587429794 hasConceptScore W2587429794C2779545874 @default.
• W2587429794 hasConceptScore W2587429794C2781413609 @default.
• W2587429794 hasConceptScore W2587429794C2908647359 @default.
• W2587429794 hasConceptScore W2587429794C2909761261 @default.
• W2587429794 hasConceptScore W2587429794C3019992690 @default.
• W2587429794 hasConceptScore W2587429794C71924100 @default.
• W2587429794 hasConceptScore W2587429794C99454951 @default.
• W2587429794 hasIssue "3" @default.
• W2587429794 hasLocation W25874297941 @default.
• W2587429794 hasLocation W25874297942 @default.
• W2587429794 hasOpenAccess W2587429794 @default.
• W2587429794 hasPrimaryLocation W25874297941 @default.
• W2587429794 hasRelatedWork W1803222855 @default.
• W2587429794 hasRelatedWork W2059277868 @default.
• W2587429794 hasRelatedWork W2071250613 @default.
• W2587429794 hasRelatedWork W2153743952 @default.
• W2587429794 hasRelatedWork W2561874300 @default.

• next